Publications in PubMed: 172
Total publications: 383
Hirsch factor (h-factor, ISI): 49

Links:
Borwin Bandelow at PubMed
Borwin Bandelow at Research Gate
Borwin Bandelow at Google Scholar

Highly Cited Papers

(As of September/October 2018, this highly cited paper received enough citations to place it in the top 1% of its academic field based on a highly cited threshold for the field and publication year.)

Bandelow B, Michaelis S. 2015. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 17:327-35.
Bandelow B, Michaelis S, Wedekind D. 2017. Treatment of anxiety disorders. Dialogues Clin Neurosci 19:93-107.
Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. 2015. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 30:183-92.
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, et al. 2014. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28:403-39.

Wissenschaftliche Publikationen/Scientific Publications

Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP, World Council of A (2003): WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 8:53-61.
Ansorg R, Gunesch D, Bandelow B, Thomssen R (1977): [Differentiation and diagnostic significance of immunoglobulin classes of antibodies against cell wall antigens of yeast and mycelial phase of Candida albicans (author’s transl)]. Mykosen 20:167-77.
Baldwin DS, Allgulander C, Altamura AC, et al (2010): Manifesto for a European anxiety disorders research network. Eur Neuropsychopharmacol 20:426-32.
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (2012): An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry 13:510-6.
Baldwin DS, Anderson IM, Nutt DJ, et al (2014): Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28:403-39.
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, British Association for P (2005): Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-96.
Baldwin DS, Bandelow B, Dolberg OT, Andersen HF, Stein DJ (2009a): Symptom improvement and functional recovery in patients with anxiety disorders. European Neuropsychopharmacology 19:S590-S591.
Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009b): How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269-75.
Bandelow B Depression : Informationen für Patienten und Angehörige. [Hamburg]: DAK.
Bandelow B Nur nicht Bange machen lassen. Harvard-Business-Manager.
Bandelow B Untersuchungen zur selektiven Züchtung der Mycel- und Blastosporenphase von Candida albicans und zur diagnostischen Wertigkeit präzipitierender Antikörper gegen Antigene der beiden Wachstumsformen.
Bandelow B (1979): DER EINFLUSS ZENTRAL WIRKSAMER PHARMAKA AUF TESTS DER INTELEKTUELLEN LEISTUNGSFÄHIGKEIT. Göttingen: Univ.
Bandelow B (1985): UNTERSUCHUNG ÜBER DIE IMPULSIVITÄT VON VERHALTENSGESTÖRTEN KINDERN MIT MCD-SYNDROM, PSYCHOREAKTIV VERHALTENSGESTÖRTEN UND NICHT VERHALTENSGESTÖRTEN KINDERN. Göttingen: Univ.
Bandelow B (1995): Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73-81.
Bandelow B (1996a): Einschränkung der Lebensqualität durch Panikstörung und Agoraphobie. Göttingen.
Bandelow B (1996b): Seminar social phobias – Clinical aspects and diagnosis of social phobias. Nervenheilkunde 15:315-318.
Bandelow B (1997): Panik- und Agoraphobie-Skala: (PAS); Handanweisung. Göttingen [u.a.]: Hogrefe.
Bandelow B (1998a): Therapie mit Antidepressiva. In Fox J, Rüther E (eds), Handbuch der Arzneimitteltherapie. Band I: Psychopharmaka. Stuttgart: Thieme, pp 65-113.
Bandelow B (1998b): Therapie mit Neuroleptika. In Fox J, Rüther E (eds), Handbuch der Arzneimitteltherapie. Band I: Psychopharmaka. Stuttgart: Thieme, pp 115-169.
Bandelow B (1999): Panic and Agoraphobia Scale (PAS): Manual. Seattle: Hogrefe & Huber Pub.
Bandelow B (2000a): [Generalized anxiety disorder]. Versicherungsmedizin 52:115-8.
Bandelow B (2000b): Spezielles zu den einzelnen Neuroleptika. In Möller HJ MW, Bandelow B. (ed), Neuroleptika. Stuttgart: Wissenschaftliche Verlagsgesellschaft, pp (in press).
Bandelow B (2000c): Therapie mit Neuroleptika Qualitätssicherung und Arzneimittelsicherheit. Darmstadt: Steinkopff.
Bandelow B (2001): Panik und Agoraphobie : Diagnose, Ursachen, Behandlung. Wien [u.a.]: Springer.
Bandelow B (2002a): [Behavior therapy and antidepressive drugs. What helps with anxiety?]. MMW Fortschr Med Suppl 2:60-2, 64-5.
Bandelow B (2002b): How long to treat anxiety disorders? European Neuropsychopharmacology 12:S159-S160.
Bandelow B (2002c): Panikstörung und Agoraphobie – Medikamentöse Behandlung. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp (im Druck).
Bandelow B (2002d): Quick sedation of the agitated patient with zyprexa velotab – Innovation in acute psychiatric care. Nervenheilkunde 21:75-76.
Bandelow B (2003a): Angst- und Panikerkrankungen. Bremen: Uni-Med.
Bandelow B (2003b): Epidemiology of Depression and Anxiety. In Kasper S, den Boer JA, Sitsen AJM (eds), Handbook on Depression and Anxiety. New York, N.Y.: M. Dekker, pp 49-68.
Bandelow B (2003c): Panikstörung und Agoraphobie – Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 77-88.
Bandelow B (2003d): Soziale Phobie – Medikamentöse Therapie. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 133-136.
Bandelow B (2003e): Soziale Phobie – Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In Bandelow B (ed), Angst- und Panikerkrankungen. Bremen: UNI-MED, pp 137-140.
Bandelow B (2004a): Das Angstbuch. 10. Aufl. Reinbek: Rowohlt.
Bandelow B (2004b): Sertraline and exposure therapy in social phobia. Br J Psychiatry 184:271; author reply 271-2.
Bandelow B (2005a): The advantages of SSRI treatment of panic disorder. Journal of Psychosomatic Research 58:S23-S23.
Bandelow B (2005b): Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann, 3. Aufl ed. Reinbek bei Hamburg: Rowohlt.
Bandelow B (2005c): S.2.6 Treatment of anxiety disorders. European Neuropsychopharmacology 15:S96.
Bandelow B (2005d): Treating anxiety disorders: Efficacy and safety considerations. European Psychiatry 20:S153-S154.
Bandelow B (2005e): Treatment of panic anxiety disorder: An update. European Psychiatry 20:S155.
Bandelow B (2006a): Angst- und Panikerkrankungen, 2. Auflage. Bremen: Uni-Med.
Bandelow B (2006b): C.10.01 Generalized anxiety disorder (GAD): the treatment implications of clinical heterogeneity. European Neuropsychopharmacology 16:S579-S579.
Bandelow B (2006c): Celebrities vom schwierigen Glück, berühmt zu sein, 1. Aufl ed. Reinbek bei Hamburg: Rowohlt.
Bandelow B (2006d): Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann, 4. Aufl ed. Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.
Bandelow B (2006e): Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 11:21-8.
Bandelow B (2006, 2. Aufl.): Celebrities – Vom schwierigen Glück, berühmt zu sein. Reinbek: Rowohlt.
Bandelow B (2007a): Celebrities: vom schwierigen Glück, berühmt zu sein. Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.
Bandelow B (2007b): Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann, 5. Aufl ed. Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.
Bandelow B (2007c): Das Buch für Schüchterne. Reinbek: Rowohlt.
Bandelow B (2007d): Das Buch für Schüchterne Wege aus der Selbstblockade, 1. Aufl. ed. Reinbek bei Hamburg: Rowohlt.
Bandelow B (2007e): Long term treatment of anxiety disorders. European Psychiatry 22:S73.
Bandelow B (2007f): New therapy options for anxiety and compulsive disorder. Nervenarzt 78:510.
Bandelow B (2007g): Pharmacological treatment of anxiety disorders – is there a state of the art? European Psychiatry 22:S90-S90.
Bandelow B (2007h): Prevalence of pain in depression. International Journal of Psychiatry in Clinical Practice 11:307.
Bandelow B (2007i): Therapy of fear disorder. Nervenarzt 78:241.
Bandelow B (2007j): Treatment-resistant panic anxiety disorder. European Neuropsychopharmacology 17:S207-S208.
Bandelow B (2008a): Celebrities (Chinese edition). Beijing: SDX Joint Publishing Company.
Bandelow B (2008b): Das Angstbuch (koreanische Ausgabe). Seoul: Puriwa Ipari Publishing Co.
Bandelow B (2008c): Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann, 6. Aufl ed. Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.
Bandelow B (2008d): Gwiazdy. Gdansk: Gdanskie Wydawnictwo.
Bandelow B (2008e): The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 13:37-46.
Bandelow B (2008f): The Medical Treatment of Obssessive-Compulsive Disorder and Anxiety. Cns Spectrums 13:37-46.
Bandelow B (2008g): Recent developments in pharmacotherapy of GAD. International Journal of Neuropsychopharmacology 11:319-319.
Bandelow B (2009a): Angst-, Panik- und Zwangsstörungen. In Ludwig WD (ed), Arzneiverordnungen, 22. Auflage. ISBN 978-3-87360-015-7: Medizinische Medien Informations GmbH, pp 395-405.
Bandelow B (2009b): Angststörungen. In Scharmer U (ed), Arzthandbuch – Wirtschaftliche und evidenzbasierte Arzneiverordnung für die Praxis. ISBN: 978-3-9809457-5-2. München: Urban & Vogel, pp 135-137.
Bandelow B (2009c): Benzodiazepines and Pregabalin in the Treatment of Generalized Anxiety Disorder. International Journal of Psychiatry in Clinical Practice 13:11-11.
Bandelow B (2009d): Comorbid depression and anxiety – understanding and treating complex patients. European Neuropsychopharmacology 19:S706-S706.
Bandelow B (2009e): Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann, 7. Aufl. ed. Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.
Bandelow B (2009f): [Eccentric life, early death. Borderline personality in the spotlight (interview by Dr. med. Brigitte Moreano)]. MMW Fortschr Med 151:6.
Bandelow B (2009g): Long-term treatment of anxiety disorders. International Journal of Psychiatry in Clinical Practice 13:19-19.
Bandelow B (2009h): Nur nicht Bange machen lassen – Gesundheitscoaching: Angst ist nichts Schlimmes, sie kann Manager auch beflügeln. Lernen Sie, mit negativen Gefühlen umzugehen. Harvard Business Manager 31:24.
Bandelow B (2010a): Rating Scales and Standardised Diagnostics in Daily Routine. European Psychiatry 25.
Bandelow B (2010b): Wenn die Seele leidet. Reinbek: Rowohlt.
Bandelow B (2011a): Embitterment syndrome: options for psychopharmacological management. In Linden M, Maercker A (eds), Embitterment – societal, psychological, and clinical perspectives. Wien: Springer, pp 187-96.
Bandelow B (2011b): EVIDENCE-BASED TREATMENT OF ANXIETY DISORDERS IN EUROPE – AN UPDATE. European Psychiatry 26.
Bandelow B (2011c): Herzrasen, Atemnot, Panik. Hebammenforum:7-14.
Bandelow B (2011d): Prominente Menschen mit Angststörungen. J Neurol Neurochir Psychiatr 12:344-347.
Bandelow B (2011e): Risks and Benefits of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder (GAD). International Journal of Psychiatry in Clinical Practice 15:3.
Bandelow B (2012): Why do celebrities die young? International Journal of Psychiatry in Clinical Practice 16:6-7.
Bandelow B (2013a): The effect of comorbid anxiety on outcomes in major depressive disorder (MDD). International Journal of Psychiatry in Clinical Practice 17:10.
Bandelow B (2013b): Wer hat Angst vorm bösen Mann? warum uns Täter faszinieren, 1. Aufl. ed. Reinbek bei Hamburg: Rowohlt.
Bandelow B (2015a): Flugangst – Woher sie kommt und wie man sie bekämpfen kann. Reinbek: Rowohlt.
Bandelow B (2015b): Generalized Anxiety Disorder and Pain. Mod Trends Pharmacopsychiatry 30:153-65.
Bandelow B (2016): Panik- und Agoraphobieskala, 2. Aufl. Göttingen: Hogrefe.
Bandelow B (2017): Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. CNS Spectr 22:404-406.
Bandelow B (2020): Current and Novel Psychopharmacological Drugs for Anxiety Disorders. In Kim Y-K (ed), Anxiety Disorders: Rethinking and Understanding Recent Discoveries. Singapore: Springer Singapore, pp 347-365.
Bandelow B, Aigner JM (1998): Therapie mit klassischen und neuen Neuroleptika. Berlin [u.a.]: Springer.
Bandelow B, Alvarez Tichauer G, Spath C, Broocks A, Hajak G, Bleich S, Ruther E (2001): Separation anxiety and actual separation experiences during childhood in patients with panic disorder. Can J Psychiatry 46:948-52.
Bandelow B, Amering M, Benkert O, Marks I, Nardi AE, Osterheider M, Tannock C, Tremper J, Versiani M (1996a): Cardio-respiratory and other symptom clusters in panic disorder. Anxiety 2:99-101.
Bandelow B, Andersen HF, Dolberg OT (2007a): Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 24:53-61.
Bandelow B, Baldwin D, Abelli M, et al (2016a): Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World J Biol Psychiatry 17:321-65.
Bandelow B, Baldwin D, Abelli M, et al (2017a): Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 18:162-214.
Bandelow B, Baldwin DS (2010): Pharmacotherapy for panic disorder. In Stein DJ, Hollander E, Rothbaum BO (eds), Textbook of Anxiety Disorders. Washington, D.C./London: American Psychiatric Publishing, pp 399-433.
Bandelow B, Baldwin DS (2020): Pharmacotherapy for panic disorder. In Simon NM, Hollander E, Rothbaum BO, Stein DJ (eds), Textbook of Anxiety, Trauma and OCD-Related Disorders. Washington, D.C./London: American Psychiatric Publishing, pp 385-398.
Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ (2006a): What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67:1428-34.
Bandelow B, Baldwin DS, Domschke K (2014a): Panic disorder and agoraphobia, Oxford Psychiatry Library, First edition ed. Oxford, United Kingdom: Oxford University Press.
Bandelow B, Baldwin DS, Zwanzger P (2013a): Pharmacological Treatment of Panic Disorder. In Baldwin DS, Leonard BE (eds), Modern trends in pharmacopsychiatry: Anxiety Disorders, Vol 29: Karger.
Bandelow B, Bassler M (2003): Angst- und Panikerkrankungen Ätiologie, Diagnostik, Therapie, 1. Aufl ed. Bremen [u.a.]: UNI-MED Verl.
Bandelow B, Bassler M (2006): Angst- und Panikerkrankungen Ätiologie, Diagnostik, Therapie, 2. Aufl. ed. Bremen [u.a.]: UNI-MED.
Bandelow B, Bauer M, Vieta E, El-Khalili N, Gustafsson U, Earley WR, Eriksson H (2014b): Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry 15:155-66.
Bandelow B, Bauer M, Vieta E, El-Khalili N, Udd M, Gustafsson U, Eriksson H (2010a): Pooled analysis of the efficacy of adjunctive quetiapine XR in patients with major depressive disorder and high or low levels of baseline anxiety. International Journal of Psychiatry in Clinical Practice 14:19-20.
Bandelow B, Behnke K, Lenoir S, Hendriks G, Alkin T, Dombrowski A, Goebel C (2002a): Sertraline versus paroxetine in the treatment of panic disorder: A multinational randomized double-blind 15 week study. European Neuropsychopharmacology 12:S364.
Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM (2004a): Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 65:405-13.
Bandelow B, Bleich S, Kropp S (2000a): Handbuch Psychopharmaka, 2., überarb. Aufl. ed. Göttingen: Hogrefe.
Bandelow B, Bleich S, Kropp S (2004b): Handbuch Psychopharmaka, 2., überarb. Aufl ed. Göttingen [u.a.]: Hogrefe.
Bandelow B, Bleich S, Kropp S (2004c): Handbuch Psychopharmaka, 2. Aufl. ed. [s.l.]: Hogrefe Verlag.
Bandelow B, Bleich S, Kropp S (2012a): Handbuch Psychopharmaka, 3. Aufl., 3., vollst. überarb. Aufl. ed. Göttingen [u.a.]: Hogrefe.
Bandelow B, Bleich S, Kropp S (2012b): Handbuch Psychopharmaka. 3., vollst. überarb. Auflage. Göttingen [u.a.]: Hogrefe.
Bandelow B, Bleich S, Kropp S, Bezchlibnyk-Butler KZ (2000b): Handbuch Psychopharmaka. Göttingen [u.a.]: Hogrefe.
Bandelow B, Bobes J, Ahokas A, Eggens I, Liu S, Brecher M (2007b): Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. International Journal of Psychiatry in Clinical Practice 11:314-315.
Bandelow B, Boerner JR, Kasper S, Linden M, Wittchen HU, Moller HJ (2013b): The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int 110:300-9; quiz 310.
Bandelow B, Boerner RJ, Kasper S, Linden M, Volz HP, Wittchen HU, Moller HJ (2007c): Drug treatment of generalized anxiety disorder (GAD) – a consensus statement. Psychopharmakotherapie 14:136-+.
Bandelow B, Boerner RJ, Kasper S, Linden M, Wittchen H-U, Moeller H-J (2013c): Regular Muscle Activity Reply. Deutsches Arzteblatt International 110:610-611.
Bandelow B, Boerner RJ, Kasper S, Linden M, Wittchen HU, Moller HJ (2013d): Correspondence (reply): In reply. Dtsch Arztebl Int 110:610-1.
Bandelow B, Brasser M (2009): Clinical suitability of GAD-7 scale compared to hospital anxiety and depression scale-A for monitoring treatment effects in generalized anxiety disorder. European Neuropsychopharmacology 19:S604-S605.
Bandelow B, Broocks A (2002a): Evaluating the efficacy of psychological therapy. Verhaltenstherapie 12:205-215.
Bandelow B, Broocks A (2002b): Wirksamkeitsuntersuchungen in der Psychotherapieforschung. Verhaltenstherapie 12:205-215.
Bandelow B, Broocks A (2006): Generalisierte Angststörungen – Hypothesen zur Ätiologie. In Bandelow B (ed), Angst- und Panikerkrankungen, 2. Auflage. Bremen: UNI-MED, pp 105-108.
Bandelow B, Broocks A, Hajak G (1995a): Die Behandlung von Angsterkrankungen mit Clomipramin – eine Analyse von Kasuistiken. TW Neurologie/Psychiatrie November:7-9.
Bandelow B, Broocks A, Pekrun G, George A, Meyer T, Pralle L, Bartmann U, Hillmer-Vogel U, Ruther E (2000c): The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry 33:174-81.
Bandelow B, Broocks B (1997): Die medikamentöse Behandlung der sozialen Phobie. In Buchheim (ed), Psychotherapie und Psychopharmaka. Stuttgart/New York: Schattauer.
Bandelow B, Brunner E, Beinroth D, Pralle L, Broocks A, Hajak G, Ruther E (1999): Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. Eur Arch Psychiatry Clin Neurosci 249:21-7.
Bandelow B, Brunner E, Broocks A, Beinroth D, Hajak G, Pralle L, Ruther E (1998a): The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res 77:43-9.
Bandelow B, Charimo Torrente A, Rüther E (2004d): The role of environmental factors in the etiology of social anxiety disorder. In Bandelow B, Stein DJ (eds), Social Anxiety Disorder. New York, N.Y.: Marcel Dekker, pp 131-142.
Bandelow B, Charimo Torrente A, Wedekind D, Broocks A, Hajak G, Ruther E (2004e): Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. Eur Arch Psychiatry Clin Neurosci 254:397-405.
Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H (2010b): Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305-20.
Bandelow B, Degner D, Kreusch U, Ruther E (1995b): Myocarditis under therapy with clozapine. Schizophr Res 17:293-4.
Bandelow B, Demyttenaere K, Papakostas G, Trivedi M, Szamosi J, Earley W, Eriksson H (2010c): EVALUATION OF THE EFFECTS OF QUETIAPINE XR MONOTHERAPY ON SLEEP DISTURBANCE IN PATIENTS WITH MDD. European Psychiatry 25.
Bandelow B, Domschke K (2015): Panic Disorder. In Stein D, Vythilingum B (eds), Anxiety Disorders and Gender. Cham: Springer.
Bandelow B, Engel K, Wedekind D (2009): [Evidence-based medicine in therapy of anxiety disorders]. MMW Fortschr Med 151:89-91.
Bandelow B, Engel K, Wedekind D, Amberger S Neurotische, somatoforme und Belastungsstörungen : Angststörungen. Psychiatriepflege und Psychotherapie : 76 Tabellen [mit 8 Filmen auf DVD].
Bandelow B, Falkai P, Gruber O, Havemann-Reinecke U (2013e): Kurzlehrbuch Psychiatrie (2. Aufl.), 2., überarb. und akt. Aufl. ed. Berlin [u.a.]: Springer.
Bandelow B, Fox JM, Rüther E (1998b): Handbuch der Arzneimitteltherapie Bd. 1 Psychopharmaka. Stuttgart [u.a.]: Thieme.
Bandelow B, Fox JM, Rüther E (1998c): Handbuch der Arzneimitteltherapie Bd. 1 Psychopharmaka : mit 16 Abbildungen und 117 Tabellen. Stuttgart [u.a.]: Thieme.
Bandelow B, Fritze J, Rüther E (1998d): Increased mortality in schizophrenia and the possible influence of antipsychotic treatment. Int J Psychiatry Clin Pract 2(Suppl2):S49-S57.
Bandelow B, Grohmann R, Rüther E (2000d): Unerwünschte Begleitwirkungen der Neuroleptika und ihre Behandlung. In Möller HJ (ed), Therapie psychiatrischer Erkrankungen, 2 ed. Stuttgart: Thieme, pp 217-235.
Bandelow B, Gruber O, Falkai P (2008a): Kurzlehrbuch Psychiatrie. Heidelberg: Steinkopff Verlag.
Bandelow B, Gutermann J, Peter H, Wedekind D (2013f): Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with depressive disorder and healthy controls. Int J Psychiatry Clin Pract 17:56-63.
Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Ruther E (1995c): Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. Int Clin Psychopharmacol 10:83-93.
Bandelow B, Haug TT (2004): Sertraline and exposure therapy in social phobia * Author’s reply. Br J Psychiatry 184:271-272.
Bandelow B, Heise CA, Banaschewski T, Rothenberger A (2006b): Handbuch Psychopharmaka für das Kindes- und Jugendalter. Göttingen: Hogrefe.
Bandelow B, Kaiya H (2006): Drug treatment for panic disorder. International Congress Series 1287:288-292.
Bandelow B, Koch M, Zimmermann P, Biesold KH, Wedekind D, Falkai P (2012c): Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospital. Eur Arch Psychiatry Clin Neurosci 262:459-67.
Bandelow B, Krause J, Wedekind D, Broocks A, Hajak G, Ruther E (2005a): Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Res 134:169-79.
Bandelow B, Lam R (2010): Escitalopram in clinical practice. ISBN 978 1 85873 439 2. London: Current Medicine Group.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel M (2011a): S3-Leitlinie Angststörungen. Heidelberg: Springer.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel M (2015a): S3-Leitlinie Angststörungen. Berlin: Springer.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME Diagnostik und Therapieempfehlungen bei Angststörungen.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME (2014c): The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int 111:473-80.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME (2014d): Diagnostik und Therapieempfehlungen bei Angststörungen. Dtsch Arztebl Int 111:473-80.
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME (2015b): The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci 265:363-73.
Bandelow B, Linden M (2009): Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. In Voderholzer U, Hohagen F, Kriegel U (eds), Therapie psychischer Erkrankungen: State of the Art 2009/2010. ISBN 978-3437249013. München: Elsevier, pp 223-242.
Bandelow B, Linden M (2011): Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung (ICD-10 F4). In Voderholzer U, Hohagen F (eds), Therapie psychiatrischer Erkrankungen, 6. Auflage. München: Elsevier, pp 193-208.
Bandelow B, Linden M (2013): Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. In Voderholzer U, Hohagen F (eds), Therapie psychischer Erkrankungen: State of the Art 2012 2013 (8. Auflage). München: Elsevier, pp 227-241.
Bandelow B, Linden M (2014): Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. In Voderholzer U, Hohagen F (eds), Therapie psychischer Erkrankungen: State of the Art 2014 (10. Auflage). München: Urban & Fischer, pp 227-241.
Bandelow B, Lueken U, Wolff J, Godemann F, Menzler CW, Deckert J, Strohle A, Beutel M, Wiltink J, Domschke K, Berger M (2016b): [Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders : How many personnel are need?]. Nervenarzt 87:302-10.
Bandelow B, Lueken U, Wolff J, Godemann F, Wolff-Menzler C, Deckert J, Strohle A, Beutel M, Wiltink J, Domschke K, Berger M (2017b): [Erratum to: Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders. How many personnel are need?]. Nervenarzt 88:290.
Bandelow B, Margraf J (1994a): Empfehlungen für die Verwendung von Messinstrumenten in der klinischen Angstforschung. Fortschr Neurol Psychiatr 62:361-5.
Bandelow B, Margraf J (1994b): [Recommendations for the use of measuring instruments in clinical anxiety research]. Fortschr Neurol Psychiatr 62:361-5.
Bandelow B, Michaelis S (2015): Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 17:327-35.
Bandelow B, Michaelis S, Wedekind D (2017c): Treatment of anxiety disorders. Dialogues Clin Neurosci 19:93-107.
Bandelow B, Muller P (1990): Paranoid-hallucinatory syndromes in multiple sclerosis. Nervenheilkunde 9:18-21.
Bandelow B, Muller P, Frick U, Gaebel W, Linden M, Muller-Spahn F, Pietzcker A, Tegeler J (1992): Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich, Federal Republic of Germany. Eur Arch Psychiatry Clin Neurosci 241:291-5.
Bandelow B, Muller P, Gaebel W, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Reischies FM, Tegeler J (1990): Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich. Eur Arch Psychiatry Clin Neurosci 240:113-20.
Bandelow B, Muller P, Ruther E (1991a): [30 years experience with haloperidol]. Fortschr Neurol Psychiatr 59:297-321.
Bandelow B, Müller P, Rüther E (1991b): 30 Jahre Erfahrung mit Haloperidol. Fortschr Neurol Psychiat 8:297-321.
Bandelow B, Pfeiffer K, Tagay S (2017d): Angststörungen im Alter.
Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D (2015c): Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 30:183-92.
Bandelow B, Rothemeyer M, Sievert K, Hajak G, Ruther E (1996b): Panic disorder – acceptance of the diagnostic entity and treatment modalities preferred by German health professionals. Eur Psychiatry 11:298-305.
Bandelow B, Ruther E (1997): Antipsychotic treatment: Recent developments and pharmacological principles. Psychopharmakotherapie 4:6-17.
Bandelow B, Ruther E (2004): Treatment-resistant panic disorder. CNS Spectr 9:725-39.
Bandelow B, Rüther E (1988): Neuroleptika in der Behandlung schizoaffektiver Psychosen. In A M (ed), Schizoaffektive Psychosen. Berlin/ Heidelberg/ New York: Springer, pp 149-58.
Bandelow B, Rüther E (1991): Serotonin und Depression. In Beckmann H, Osterheider M (eds), Neurotransmitter und psychische Erkrankungen. Berlin: Springer, pp 149-158.
Bandelow B, Rüther E (1993): Besonderheiten der Psychopharmakotherapie bei psychischen Kranken mit körperlichen Erkrankungen. In Möller H-J (ed), Therapie psychiatischer Erkrankungen. Stuttgart: Enke.
Bandelow B, Rüther E (1997): Antipsychotische Behandlung: jüngste Weiterentwicklungen und pharmakologischen Grundlagen. Psychopharmakotherapie 4:6-17.
Bandelow B, Rüther E (1998a): Anwendung von Neuroleptika bei psychischen Störungen im Rahmen internistischer Erkrankungen. In Gaebel W. KA (ed), Neuroleptika bei nicht-psychotischen Störungen, Vol 166-174. Berlin/ Heidelberg/ New York: Springer.
Bandelow B, Rüther E (1998b): Unerwünschte Wirkungen der Neuroleptika – Extrapyramidalmotorische Wirkungen. In Bandelow B RE (ed), Therapie mit klassischen Neuroleptika – heute und morgen. Berlin/ Heidelberg/ New York: Springer.
Bandelow B, Rüther E (2000): Besonderheiten der Psychopharmaka-Therapie bei psychisch Kranken mit körperlichen Erkrankungen. In Möller HJ (ed), Therapie psychiatrischer Erkrankungen, 2 ed. Stuttgart: Thieme, pp 1176-1184.
Bandelow B, Sagebiel A, Belz M, Gorlich Y, Michaelis S, Wedekind D (2018a): Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry 212:333-338.
Bandelow B, Sagebiel A, Belz M, Görlich Y, Michaelis S, Wedekind D (2018b): Authors’ reply. British Journal of Psychiatry 214:53-54.
Bandelow B, Saleh K, Pauls J, Domschke K, Wedekind D, Falkai P (2010d): Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect? World J Biol Psychiatry 11:66-70.
Bandelow B, Schmahl C, Falkai P, Wedekind D (2010e): Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev 117:623-36.
Bandelow B, Schmahl C, Falkai P, Wedekind D (2011b): BORDERLINE PERSONALITY DISORDER – A DYSREGULATION OF THE ENDOGENOUS OPIOID SYSTEM? European Psychiatry 26.
Bandelow B, Schuller K (2020): Mean age and gender distribution of patients with major mental disorders participating in clinical trials. Eur Arch Psychiatry Clin Neurosci 270:655-659.
Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E (2007d): Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 8:175-87.
Bandelow B, Sengos G, Wedekind D, Huether G, Pilz J, Broocks A, Hajak G, Ruther E (1997): Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. Pharmacopsychiatry 30:113-7.
Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ, Care WTFoMDiP, Wfsbp Task Force on Anxiety Disorders OCD, Ptsd (2012d): Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77-84.
Bandelow B, Sievert K, Rothemeyer M, Hajak G, Broocks A, Ruther E (1995d): [Panic disorder and agoraphobia: what is effective?]. Fortschr Neurol Psychiatr 63:451-64.
Bandelow B, Sievert K, Rothemeyer M, Hajak G, Broocks A, Rüther E (1995e): Panikstörung und Agoraphobie: Was wirkt? Fortschr Neurol Psychiatr 63:451-64.
Bandelow B, Sievert K, Röthemeyer M, Hajak G, Broocks A, Rüther E (1996c): Panikstörung und Agoraphobie: Welche Behandlung erhalten die Patienten? Psychopharmakotherapie (accepted for publication).
Bandelow B, Sievert K, Rothemeyer M, Hajak G, Ruther E (1995f): What treatments do patients with panic disorder and agoraphobia get? Eur Arch Psychiatry Clin Neurosci 245:165-71.
Bandelow B, Sojka F, Broocks A, Hajak G, Bleich S, Ruther E (2006c): Panic disorder during pregnancy and postpartum period. Eur Psychiatry 21:495-500.
Bandelow B, Spath C, Tichauer GA, Broocks A, Hajak G, Ruther E (2002b): Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. Compr Psychiatry 43:269-78.
Bandelow B, Stein DJ (2004a): Pharmacotherapy of social anxiety disorder. In Bandelow B, Stein DJ (eds), Social Anxiety Disorder. New York, N.Y.: Marcel Dekker, pp 267-298.
Bandelow B, Stein DJ (2004b): Social anxiety disorder. New York: Marcel Dekker.
Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007e): Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40:152-6.
Bandelow B, Vieta E, El-Khalili N, Bauer M, Nyberg S, Eriksson H (2011c): Adjunct Quetiapine Xr in Patients with Major Depressive Disorder: A Pooled Analysis of Data from Patients with Anxious Depression. European Psychiatry 26.
Bandelow B, Wedekind D (2006): Angst – Neurobiologie. In Förstl H, Hautzinger M, Roth G (eds), Neurobiologie psychischer Störungen. Heidelberg: Springer, pp 483-522.
Bandelow B, Wedekind D (2014): [Social phobia]. Nervenarzt 85:635-44; quiz 645-7.
Bandelow B, Wedekind D (2015): Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. Hum Psychopharmacol 30:393-415.
Bandelow B, Wedekind D (2019): Network analyses to rank pharmacological treatments for generalised anxiety disorder. Lancet 393:721-722.
Bandelow B, Wedekind D, Leon T (2007f): Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7:769-81.
Bandelow B, Wedekind D, Pauls J, Broocks A, Hajak G, Ruther E (2000e): Salivary cortisol in panic attacks. Am J Psychiatry 157:454-6.
Bandelow B, Wedekind D, Sandvoss V, Broocks A, Hajak G, Pauls J, Peter H, Ruther E (2000f): Diurnal variation of cortisol in panic disorder. Psychiatry Res 95:245-50.
Bandelow B, Wiltink J, Alpers GW, et al (2014e): S3-Leitlinie zur Behandlung von Angststörungen.
Bandelow B, Wolff-Menzler C, Wedekind D, Ruther E (2006d): Anxiety disorders: Long-term treatment and relapse prevention. Mmw-Fortschritte Der Medizin 148:31-34.
Bandelow B, Wolff-Menzler C, Wedekind D, Rüther E (2006e): Patienten mit Angst- und Panikstörungen – Wie lange muss behandelt werden? MMW-Fortschr.Med. 148:31-34.
Bandelow B, World Federation of Societies of Biological Psychiatry (2005): Medikamentöse Behandlung von Angst- und Zwangs- und posttraumatischen Belastungsstörungen : Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart: Wiss. Verl.-Ges.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (2005b): Leitlinien der World Federation of Societies of Biological Psychiatry (WFSBP) für die medikamentöse Behandlung von Angst-, Zwangs- und posttraumatischen Belastungsstörungen. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
Bandelow B, Zohar J, Hollander E, et al (2008b): World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248-312.
Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety O-C, Posttraumatic Stress D (2002c): World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-99.
Bandelow B, Zohar J, Kasper S, Moller HJ (2008c): How to grade categories of evidence. World J Biol Psychiatry 9:242-7.
Bleich S, Bandelow B, Javaheripour K, Muller A, Degner D, Wilhelm J, Havemann-Reinecke U, Sperling W, Ruther E, Kornhuber J (2003): Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett 335:179-82.
Bleich S, Degner D, Bandelow B, von Ahsen N, Ruther E, Kornhuber J (2000): Plasma homocysteine is a predictor of alcohol withdrawal seizures. Neuroreport 11:2749-52.
Bleisch B, Bandelow B, Gmür A Sternstunde Philosophie 2015.03.01 […].
Broocks A, Bandelow B (1999a): Drs. Broocks and Bandelow Reply. Am J Psychiatry 156:1129a-1130.
Broocks A, Bandelow B (1999b): Fetal alcohol exposure and adult psychiatric disorders – Dr. Broocks and Bandelow reply. American Journal of Psychiatry 156:1129-1130.
Broocks A, Bandelow B, George A, Jestrabeck C, Opitz M, Bartmann U, Gleiter CH, Meineke I, Roed IS, Ruther E, Hajak G (2000a): Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15:153-61.
Broocks A, Bandelow B, George A, Roed I (2001a): Increased psychobehavioral responsiveness to M-chlorophenylpiperazine (m-CPP) and ipsapirone (IPS) in patients with panic disorder (PDA). Journal of Neurochemistry 78:81.
Broocks A, Bandelow B, Koch K, Bartmann U, Kinkelbur J, Schweiger U, Hohagen F, Hajak G (2002): Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder. Neuropsychopharmacology 27:270-8.
Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E (1998): Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155:603-9.
Broocks A, Junghanns K, Thiel A, Gleiter CH, Bandelow B (2000b): Advances in the pharmacotherapy of depression by new antidepressants. Fortschritte Der Neurologie Psychiatrie 68:17-24.
Broocks A, Junghanns K, Thiel A, Gleiter CH, Bandelow B (2000c): [New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation]. Fortschr Neurol Psychiatr 68:17-24.
Broocks A, Meyer T, George A, Hillmer-Vogel U, Meyer D, Bandelow B, Hajak G, Bartmann U, Gleiter CH, Ruther E (1999a): Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology 20:150-61.
Broocks A, Meyer T, Gleiter CH, Hillmer-Vogel U, George A, Bartmann U, Bandelow B (2001b): Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. Psychopharmacology (Berl) 155:234-41.
Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A, Pekrun G, Wedekind D, Ruther E, Bandelow B (2003): 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 13:153-64.
Broocks A, Meyer TF, Bandelow B, George A, Bartmann U, Ruther E, Hillmer-Vogel U (1997a): Exercise avoidance and impaired endurance capacity in patients with panic disorder. Neuropsychobiology 36:182-7.
Broocks A, Meyer TF, George A, Pekrun G, Hillmer-Vogel U, Hajak G, Bandelow B, Ruther E (1997b): [Value of sports in treatment of psychiatric illness]. Psychother Psychosom Med Psychol 47:379-93.
Broocks A, Meyer TF, George A, Pekrun G, HillmerVogel U, Hajak G, Bandelow B, Ruther E (1997c): The role of exercise in the treatment of psychiatric disorders. Psychotherapie Psychosomatik Medizinische Psychologie 47:379-393.
Broocks A, Peters M, Bandelow B, Ruther E (1999b): Physical activity and affective diseases. Verhaltenstherapie 9:7-8.
Broocks A, Rüther E, Munzel U, Hajak G, Wedekind D, Bandelow B (2000d): FC04.01 Responsiveness of central serotonin receptors in panic disorder: Effects of clomipramine treatment and exercise. European Psychiatry 15:243s-243s.
Buchheim P, Bandelow B (1997): Psychotherapie und Psychopharmaka : störungsorientierte Behandlungsansätze – kombinierte Therapie. Stuttgart [u.a.]: Schattauer.
Bundesgesetzblatt (2008): Anlage „Versorgungsmedizinische Grundsätze“. Anlageband zum Bundesgesetzblatt Teil I Nr. 57 vom 15. Dezember 2008. Anlage zu § 2 der Versorgungsmedizin-Verordnung vom 10. Dezember 2008. 1. bis 5. Verordnung zur Änderung der Versorgungsmedizin-Verordnung vom 11.10.2012 (Anlage zum Bundesgesetzblatt Teil I Nr. 57 vom 15. Dezember 2008 sowie Bundesgesetzblatt Teil I Nr. 47 vom 16.10.2012).
Busch S, et al. (2009): Diagnostik der Beschwerdenvalidität: praktische Gesichtspunkte und medizinische Erfordernisse. In Merten T, Dettenborn H (eds), Diagnostik der Beschwerdenvalidität. Berlin: Deutscher Psychologen Verlag.
Degner D, Bandelow B, Akkan R, Kropp S, Nietmann PD, Ruther E, Bleich S (2003): Relevance of therapeutic drug monitoring (TDM) in patients with quetiapine administration. Pharmacopsychiatry 36:219-219.
Degner D, Bleich S, Grohmann R, Bandelow B, Ruther E (2000): Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry 34:880.
Degner D, Fiege O, Bandelow B, Grohmann R, Ruther E (2005): Oculogyric crisis under aripiprazol in combination with fluoxetin. Psychopharmakotherapie 12:32-33.
Degner D, Knievel A, Muller P, Bandelow B, Schaefer E, Grohmann R, Ruther E (2004a): Acute agranulocytosis after long-term clozapine treatment. Psychopharmakotherapie 11:98-100.
Degner D, Knievel A, Müller P, Bandelow B, Schaefer E, Grohmann R, Rüther E (2004b): Akute Agranulozytose nach langjähriger Clozapinbehandlung. Psychopharmakotherapie 11:98-100.
Doering S, Wedekind D, Pilz J, Bandelow B, Adler L, Huether G (2001): [Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology]. Z Psychosom Med Psychother 47:42-57.
Domschke K, Hohoff C, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Kastner F, Rothermundt M, Arolt V, Deckert J (2008): Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. Am J Med Genet B Neuropsychiatr Genet 147B:510-6.
Domschke K, Reif A, Weber H, et al (2011): Neuropeptide S receptor gene — converging evidence for a role in panic disorder. Mol Psychiatry 16:938-48.
DRV (2012): Leitfaden für die sozialmedizinische Begutachtung – Deutsche Rentenversicherung: Deutsche Rentenversicherung.
Engel K, Bandelow B, Gruber O, Wedekind D (2009): Neuroimaging in anxiety disorders. J Neural Transm (Vienna) 116:703-16.
Engel KR, Bandelow B, Neumann C, Obst K, Wedekind D (2012): Disorder-specific emotional imagery for differential and quantitative assessment of agoraphobia. Curr Pharm Des 18:5638-44.
Engel KR, Obst K, Bandelow B, Dechent P, Gruber O, Zerr I, Ulrich K, Wedekind D (2016): Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls. Eur Arch Psychiatry Clin Neurosci 266:557-66.
Enkling N, Jöhren HP, Bürklein S, Lenk M, Margraf-Stiksrud J, Beck G, Daubländer M, Wölber J, Wannemüller A, Dünniger D, Bandelow B, Benecke A (2019): S3-Leitlinie Zahnbehandlungsangst beim Erwachsenen. Arbeitskreis Psychologie und Psychosomatik in der DGZMK (AKPP), Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde (DGZMK) – Langversion.
Erhardt A, Czibere L, Roeske D, et al (2011): TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 16:647-63.
Erhardt A, Lucae S, Kern N, et al (2008): Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks. Mol Psychiatry 13:242-3.
Fritze J, Bandelow B (1998a): The QT-interval and the new, atypical neuroleptic sertindole. Psychopharmakotherapie 5:115-120.
Fritze J, Bandelow B (1998b): The QT interval and the atypical antipsychotic, sertindole. Int J Psychiatry Clin Pract 2:265-73.
Gade K, Haussinger C, Bandelow B (2009): Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone. Pharmacopsychiatry 42:164-5.
Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J, World Council of A (2003): WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 8:7-16.
Hajak G, Bandelow B (1992): Angst und Schlafstörungen. München: Medizin Verlag.
Hajak G, Bandelow B (1994): Pharmacotherapy of Insomnia in General-Practice. Medizinische Welt 45:258-263.
Hajak G, Bandelow B (1996): [Coincidence of anxiety and sleep disorders. Overview and case reports]. Fortschr Neurol Psychiatr 64:26-40.
Hajak G, Bandelow B (1998): Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 13:157-67.
Hajak G, Bandelow B, Zulley J, Pittrow D (2002): “As needed” pharmacotherapy combined with stimulus control treatment in chronic insomnia–assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 14:1-7.
Hajak G, Clarenbach P, Fischer W, Haase W, Bandelow B, Adler L, Ruther E (1995a): Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. Eur Psychiatry 10 Suppl 3:173s-9s.
Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B, Broocks A, Ruther E (1998): Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 248:148-56.
Hajak G, Rodenbeck A, Adler L, Huether G, Bandelow B, Herrendorf G, Staedt J, Ruther E (1996a): Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 29:187-92.
Hajak G, Rodenbeck A, Bandelow B, Friedrichs S, Huether G, Ruther E (1996b): Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. Eur Neuropsychopharmacol 6:149-53.
Hajak G, Rodenbeck A, Herrendorf G, Staedt J, Bandelow B, Huether G, Rüther E Reduced nocturnal melatonin plasma concentration in patients with chronic primary insomnia. Pineal Res in press.
Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Ruther E (1995b): Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res 19:116-22.
Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Moller HJ, Kasper S, Chairs WGTF (2019): WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World J Biol Psychiatry 20:2-16.
Haug BA, Hermsteiner EM, Bandelow B, Paulus W (1997): Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson’s disease and in neuroleptic treatment. Vision Res 37:3535-47.
Heindl S, Binder C, Desel H, Matthies U, Lojewski I, Bandelow B, Kahl GF, Chemnitius JM (2000): [Etiology of initially unexplained confusion of excitability in deadly nightshade poisoning with suicidal intent. Symptoms, differential diagnosis, toxicology and physostigmine therapy of anticholinergic syndrome]. Dtsch Med Wochenschr 125:1361-5.
Hohoff C, Jung A, Freitag CM, Willis-Owen SA, Ponath G, Krakowitzky P, Fritze J, Bandelow B, Franke P, Fimmers R, Nothen MM, Flint J, Deckert J (2005): Investigation of RGS2 and RGS13 gene polymorphisms in human panic disorder (Poster abstract). American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 138b:11-11.
Hohoff C, Mullings EL, Heatherley SV, et al (2010): Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. J Psychiatr Res 44:930-7.
Hohoff C, Neumann A, Domschke K, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Rothermundt M, Arolt V, Deckert J (2009): Association analysis of Rgs7 variants with panic disorder. J Neural Transm (Vienna) 116:1523-8.
Hohoff C, Weber H, Richter J, et al (2015): RGS2 ggenetic variation: association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. Am J Med Genet B Neuropsychiatr Genet 168B:211-22.
Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B (2009): Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24:87-96.
Keck ME, Kern N, Erhardt A, et al (2008): Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1196-204.
Klöppel S, Jessen F, Albus C, Assion H-J, Bandelow B (2017): Praxishandbuch Gerontopsychiatrie und -psychotherapie Diagnostik und Therapie im höheren Lebensalter, 1. Auflage ed.
Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I (2005): Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 38:24-9.
Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J, Franke P, Bandelow B, Fimmers R, Flint J, Deckert J (2006): Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm (Vienna) 113:1921-5.
Linden M, Bandelow B, Boerner RJ, Brasser M, Kasper S, Moller HJ, Pyrkosch L, Volz HP, Wittchen HU (2013): The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm”. Int J Psychiatry Clin Pract 17:78-89.
Link S, Paulus W, Bandelow B (2009): Remission of acute psychotic anxious depression in a patient with Parkinson’s disease after treatment with quetiapine. Mov Disord 24:2431-2.
Lyndon GJ, Prieto R, Wajsbrot DB, Allgulander C, Bandelow B (2019): Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol 34:110-118.
Madhukar HT, Bandelow B, Demyttenaere K, Papakostas G, I, Szamosi J, Earley W, Eriksson H (2015): Erratum. Int J Neuropsychopharmacol 18.
Margraf J, Bandelow B (1997): Recommendations on assessment instruments for clinical research. Zeitschrift Fur Klinische Psychologie-Forschung Und Praxis 26:150-156.
Meiser M, Dupper F, Wedekind D, Bandelow B (2015): Improvement of Borderline Personality Disorder with Naltrexone: Results of a Retrospective Evaluation. European Psychiatry 30.
Meyer T, Broocks A, Bandelow B, Hillmer-Vogel U, Ruther E (1998): Endurance training in panic patients: spiroergometric and clinical effects. Int J Sports Med 19:496-502.
Möller H-J, Bandelow B (2002): Moderne Antidepressiva : 31 Tabellen. Stuttgart [u.a.]: Thieme.
Möller H-J, Bandelow B (2006): Innovation und Wandel der antidepressiven Therapie in Deutschland : 24 Tab. Stuttgart [u.a.]: Thieme.
Möller H-J, Müller WE, Bandelow B (2001): Neuroleptika : pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen ; mit 136 Tabellen. Stuttgart: Wiss. Verl.-Ges.
Moller HJ, Angermeyer MC, Bandelow B, Deuschle M, Kissling W, Linden M, Naber D, Schmauss M, Voderholzer U (2007): Compliance in schizophrenia and comparable psychotic disorders. Psychopharmakotherapie 14:14-22.
Moller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W (2015a): DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences–part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci 265:5-18.
Moller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W (2015b): DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci 265:87-106.
Moller HJ, Bandelow B, Volz HP, Barnikol UB, Seifritz E, Kasper S (2016): The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 266:725-736.
Moller HJ, Brasser M, Kasper S, Volz HP, Boerner RJ, Bandelow B (2009): Effectiveness and tolerability of pregabalin in patients with generalized anxiety disorders in routine clinical care. Psychopharmakotherapie 16:211-+.
Möller HJ, Brasser M, Kasper S, Volz HP, Boerner RJ, Bandelow B (2009): Wirksamkeit und Verträglichkeit von Pregabalin bei Patienten mit generalisierten Angststörungen in der täglichen Praxis. Psychopharmakotherapie 16:211-217.
Möller HJ, Müller WE, Bandelow B (2000): Neuroleptika. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
Muller P, Bandelow B, Gaebel W, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Schaefer E, Tegeler J (1992): Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification. Br J Psychiatry Suppl:140-4.
Muller P, Gaebel W, Bandelow B, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Tegeler J (1998a): [The social status of schizophrenic patients]. Nervenarzt 69:204-9.
Muller P, Gaebel W, Bandelow B, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Tegeler J (1998b): Zur sozialen Situation schizophrener Patienten. Der Nervenarzt 69:204-209.
Munzel U, Bandelow B (1998): The use of parametric vs. nonparametric tests in the statistical evaluation of rating scales. Pharmacopsychiatry 31:222-4.
Muscatello MR, Spina E, Bandelow B, Baldwin DS (2012): Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol 27:239-53.
Naber D, Bandelow B, Bender S, Klimke A, Kuhn K, Lambert M, Lemmer W, Riedel M, Vorbach E, Dittmann RW (2001): Subjective well-being under neuroleptic treatment with olanzapine versus clozapine: First results from a double-blind clinical trial using the SWN self-rating scale. Schizophrenia Research 49:240-240.
Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW (2005): Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111:106-15.
Neumann M-C, Bandelow B, Bandelow B, Fuchs E Störungsspezifische, visuelle emotionale Stimuli bei der Agoraphobie mit Panikstörung.
Papakostas G, Bandelow B, Demyttenaere K, Trivedi M, Earley W, Szamosi J, Eriksson H (2010): Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy on sleep disturbance in patients with major depressive disorder. International Journal of Neuropsychopharmacology 13:159-159.
Passie T, Schneider U, Borsutzky M, Breyer R, Emrich HM, Bandelow B, Schmid-Ott G (2013): Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm. Psychol Health Med 18:363-74.
Pauls J, Bandelow B, Ruther E, Kornhuber J (2000): Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder. J Neural Transm (Vienna) 107:1361-6.
Paulus W, Hermsteiner E, Haug B, Bandelow B (1995): Increment Threshold and Postadaptation Threshold Are Increased in Parkinsons-Disease. Investigative Ophthalmology & Visual Science 36:S227-S227.
Peter H, Bandelow B, Krausz M (1998a): Bedeutung des zentralen Serotoninsystems bei Alkoholabhängigkeit und therapeutische Konsequenzen. Fortschritte der Neurologie· Psychiatrie 66:459-465.
Peter H, Bandelow B, Krausz M (1998b): [The impact of the central serotonin system on alcoholism and therapeutic consequences]. Fortschr Neurol Psychiatr 66:459-65.
Pini S, Abelli M, Costa B, Martini C, Schiele MA, Baldwin DS, Bandelow B, Domschke K (2021): Separation anxiety and measures of suicide risk among patients with mood and anxiety disorders. Separation Anxiety and Suicide Risk.
Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP, World Council of A (2003): WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 8:17-30.
Prange H, Bandelow B, Prange B (2002): Notfallbuch Neurologie : vom Syndrom zur Therapie ; mit 177 Tabellen. Stuttgart: Wiss. Verl.-Ges.
Reimers CD, Bandelow B (2003): Neurologie, Psychiatrie und Sport : 48 Tabellen. Stuttgart [u.a.]: Thieme.
Remmel A, Bandelow B (2006): Handbuch Körper und Persönlichkeit : Entwicklungspsychologie, Neurobiologie und Therapie von Persönlichkeitsstörungen ; mit 53 Tabellen. Stuttgart [u.a.]: Schattauer.
Ringel E (1953): Der Selbstmord. Abschluß einer krankhaften Entwicklung. Wien/ Düsseldorf Maudrich.
Sandmann J, Lorch B, Bandelow B, Hartter S, Winter P, Hiemke C, Benkert O (1998): Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 31:117-21.
Schiele MA, Bandelow B, Baldwin DS, Pini S, Domschke K (2020): A neurobiological framework of separation anxiety and related phenotypes. Eur Neuropsychopharmacol 33:45-57.
Schreier E, Bandelow B, Mausberg R, Nitsche M Die Wirkung der EKT bei pharmakoresistenten affektiven und schizophreniformen Störungen.
Schubert K, Bandelow NC (2014): Lehrbuch der Politikfeldanalyse, Lehr- und Handbücher der Politikwissenschaft, 3., aktualisierte und überarb. Aufl. ed. Berlin: De Gruyter Oldenbourg.
Sehmer-Kurz K, Stiens G, Bandelow B (2006): Therapie der Depression und Angst im Alter. Der Neurologe und Psychiater:31-38.
SIMEN S, HAJAK G, SCHLAF G, WESTENHOFER J, RODENBECK A, BANDELOW B, PUDEL V, RUTHER E (1995a): CHRONIC SLEEP COMPLAINTS – RESULTS OF A REPRESENTATIVE SURVEY IN GERMANY. Nervenarzt 66:686-695.
Simen S, Hajak G, Schlaf G, Westenhofer J, Rodenbeck A, Bandelow B, Pudel V, Ruther E (1995b): [Chronification of sleep disorders. Results of a representative survey in West Germany]. Nervenarzt 66:686-95.
Sprute AJ, Bandelow B Eine Untersuchung zur Wirkung von Paroxetin versus Placebo in Kombination mit regelmäßigem Ausdauertraining oder Entspannungstraining auf den Kortisolwert im Nachturin von Patienten mit einer Panikstörung mit und ohne Agoraphobie.
Stein D, Kalali A, Bandelow B, Katzman MA, Olausson B, Eriksson H (2010a): Efficacy of extended release quetiapine fumarate monotherapy in patients with generalised anxiety disorder : Results from 5 placebo-controlled trials. International Journal of Neuropsychopharmacology 13:118-119.
Stein DJ, Baldwin DS, Bandelow B, Blanco C, Fontenelle LF, Lee S, Matsunaga H, Osser D, Stein MB, van Ameringen M (2010b): A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep 12:471-7.
Stein DJ, Baldwin DS, Dolberg O, Despiegel N, Bandelow B (2006a): P.4.d.002 Which factors predict placebo response in anxiety disorders and major depression? European Neuropsychopharmacology 16:S468.
Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B (2006b): Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 67:1741-6.
Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B (2007): More on placebo response – Reply. Journal of Clinical Psychiatry 68:1984-1985.
Stein DJ, Bandelow B (2004): Future Directions. In Bandelow B, Stein DJ (eds), Social Anxiety Disorder. New York: Marcel Dekker, pp 335-344.
Stein DJ, Bandelow B, Dolberg OT, Andersen HF, Baldwin DS (2008): How are symptom severity and functional recovery/relapse related? An analysis of the escitalopram database. European Psychiatry 23:S369-S369.
Stein DJ, Bandelow B, Dolberg OT, Andersen HF, Baldwin DS (2009): Anxiety symptom severity and functional recovery or relapse. Ann Clin Psychiatry 21:81-8.
Stein DJ, Bandelow B, Hollander E, Nutt DJ, Okasha A, Pollack MH, Swinson RP, Zohar J, World Council of A (2003): WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr 8:31-9.
Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H (2011): Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol 26:614-28.
Stolpmann G, Stolpmann G, Muller JL, et al Themenschwerpunkt: Teilgebiete der Psychiatrie und Psychotherapie: Bekanntes und neue Entwicklungen (Mit 6 Einzelbeitragen).
Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, Taylor R, Mantingh T, de Angel V, Patrick F, Cleare AJ, Young AH (2019): Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry 214:42-51.
Stubner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, Muller-Oerlinghausen B, Moller HJ, Hippius H, Ruther E (2004): Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 37 Suppl 1:S70-8.
Timaus C, Meiser M, Bandelow B, Engel KR, Paschke AM, Wiltfang J, Wedekind D (2019): Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry 19:393.
Trenckmann U, Bandelow B (1999): Psychiatrie und Psychotherapie. Darmstadt: Steinkopff.
Trenckmann U, Bandelow B (2002): Psychiatrie und Psychotherapie in Deutsch, Polnisch, Russisch und Türkisch. Darmstadt: Steinkopff.
Trivedi MH, Bandelow B, Demyttenaere K, Papakostas GI, Szamosi J, Earley W, Eriksson H (2013): Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol 16:1733-44.
Tural U, Fidane H, Alkin T, Bandelow B (2002): Assessing the severity of panic disorder and agoraphobia: validity, reliability and objectivity of the Turkish translation of the Panic and Agoraphobia Scale (P&A). J Anxiety Disord 16:331-40.
Tural Ü, Fidaner H, Alkın T, Bandelow B (2000): Panik Agorafobi Ölçeğinin güvenirlik ve geçerliği. Turk Psikiyatri Derg 11:29-39.
Uhlmann A, Bandelow B, Stein DJ, Bloch S, Engel KR, Havemann-Reinecke U, Wedekind D (2019): Grey matter structural differences in alcohol-dependent individuals with and without comorbid depression/anxiety-an MRI study. Eur Arch Psychiatry Clin Neurosci 269:285-294.
Van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP, World Council of A (2003): WCA recommendations for the long-term treatment of social phobia. CNS Spectr 8:40-52.
Voderholzer U, Hohagen F, Adli M, et al (2017): Therapie psychischer Erkrankungen State of the Art 2018, 13. Auflage ed.
Völker S, Knopp G, Trampe A, Bandelow B, Hanemann B, Haag-Kirchner P, Fless F (2009): Idole: Annäherung an einen vagen Begriff. ISBN 978-3938832516. München: Edition Minerva.
Weber H, Scholz CJ, Domschke K, et al (2012): Gender differences in associations of glutamate decarboxylase 1 gene (GAD1) variants with panic disorder. PLoS One 7:e37651.
Wedekind D, Bandelow B (2004): [Anxiety-ridden patients in the doctor’s office]. MMW Fortschr Med 146:24-6.
Wedekind D, Bandelow B (2005): [The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology]. Nervenarzt 76:888-91.
Wedekind D, Bandelow B (2009): Quantifizierungs-Inventar für somatoforme Syndrome QUISS ; Manual. Göttingen [u.a.]: Hogrefe.
Wedekind D, Bandelow B (2015): Psychiatrische Notfälle. In Blaschke S, Walcher F (eds), SOP Handbuch Interdisziplinäre Notaufnahme. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, pp 227-250.
Wedekind D, Bandelow B, Broocks A, Hajak G, Ruther E (2000): Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm (Vienna) 107:831-7.
Wedekind D, Bandelow B, Fentzahn E, Trumper P, Ruther E (2007a): The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity. Eur Arch Psychiatry Clin Neurosci 257:153-63.
Wedekind D, Bandelow B, Heitmann S, Havemann-Reinecke U, Engel KR, Huether G (2013): Attachment style, anxiety coping, and personality-styles in withdrawn alcohol addicted inpatients. Subst Abuse Treat Prev Policy 8:1.
Wedekind D, Bandelow B, Ruther E (2005): [Pharmacotherapy in personality disorders]. Fortschr Neurol Psychiatr 73:259-67.
Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B (2010a): A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry 11:904-13.
Wedekind D, Broocks A, Weiss N, Rotter-Glattkowski P, Engel K, Neubert K, Bandelow B (2007b): Controlled study for effectiveness of sport vs. relaxation training in combination with paroxetine vs. Placebo in the treatment of the panic disorder. Nervenarzt 78:510-510.
Wedekind D, Engel K, Bandelow B (2007c): [Early detection of anxiety disorders]. MMW Fortschr Med 149:32-5.
Wedekind D, Engel K, Bandelow B (2008a): [Social anxiety disorder–diagnostics and treatment options]. Fortschr Neurol Psychiatr 76:616-20; quiz 621-4.
Wedekind D, Gruber O, Obst K, Dechent P, Engel KR, Ulrich K, Bandelow B (2011): Functional Mri Activation in Response to Panic-Specific, Non-Panic Aversive, and Neutral Imagery in Patients with Panic Disorder and Healthy Controls. European Psychiatry 26.
Wedekind D, Herchenhein T, Kirchhainer J, Bandelow B, Falkai P, Engel K, Malchow B, Havemann-Reinecke U (2010b): Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. J Psychiatr Res 44:1163-9.
Wedekind D, Herchenhein T, Kirchhainer S, Bandelow B, Engel K, Malchow B, Falkai P, Havermann-Reinecke U (2008b): Serotonergic function, substance craving, and psychopathology in detoxified alcohol addicted males undergoing tryptophane depletion. International Journal of Neuropsychopharmacology 11:241-241.
Wedekind D, Sprute A, Broocks A, Huther G, Engel K, Falkai P, Bandelow B (2008c): Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. Curr Pharm Des 14:3518-24.
Wiltfang J, Schenk-Dapra B, Stiens G, Bleich S, Bandelow B, Muller P, Niedmann PD, Armstrong VW, Ruther E (2001): Clozapine-associated elevation of plasma cholinesterase. Eur Arch Psychiatry Clin Neurosci 251:269-71.
Wittchen HU, Linden M, Schwarzer W, Riemann D, Boerner RJ, Bandelow B (2001): [Generalized anxiety disorders (GAD)–a neglected illness? Background und aims of the GAD-P study]. Fortschr Med Orig 119 Suppl 1:1-4.
Wobrock T, Bandelow B, Reinecke UH, Wedekind D (2010): Update psychiatry – alcohol addiction anxiety disorders major-depressive disorder schizophrenia. Nervenheilkunde 29:734-+.
Wolff-Menzler C, Bandelow B (2010): [The weeping patient]. MMW Fortschr Med 152:29-30.
Zerr I, Bandelow B, Wedekind D, Schneider A, Radenbach K, Wiltfang J, Bähr M (2016): Neuropsychiatrische Erkrankungen und Demenzen: ein interdisziplinärer Ansatz. Aktuelle Neurologie 43:369-371.
Zwanzger P, Singewald N, Bandelow B (2021): [Pharmacotherapy of anxiety disorders-Guideline-conform treatment and new developments]. Nervenarzt.